Experimental immune cell therapy tested in one patient with advanced gynecological cancer
NCT ID NCT06834542
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This early-phase study tested an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological tumors. Only one participant was enrolled before the study was terminated. The goal was to check safety and see if tumors shrank, but no conclusions can be drawn from such a small, stopped trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT GYNECOLOGICAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Jiaotong University School of Medcine, Renji Hospital Ethica Committee
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.